Active Pharmaceutical Ingredient Market is Expected to Surpass US$ 225.2 Bn by 2025

An active pharmaceutical ingredient is used in a finished pharmaceutical product (FPP), intended to carry certain pharmacological actions or otherwise have a direct effect in the diagnosis, cure, treatment, mitigation or prevention of various diseases, or in some cases in restoring, correcting or modifying human physiological functions. Sales of pharmaceutical ingredient are on the rise due to a substantial increase in high-potency API (HPAPI) and peptide API manufacturing. A new study conducted by Persistence Market Research reveals that the US$ 151.9 Bn global active pharmaceutical ingredient market will grow to US$ 158.3 Bn by 2017 end, reflecting a Y-o-Y growth rate of 4.2%. This market is estimated to further increase to US$ 225.2 Bn, expanding at a CAGR of 4.5% over the forecast period (2016 – 2025)

 
Higher emphases on the development of novel therapeutics that contain high-potency active pharmaceutical ingredients (HPAPIs). Ramped-up investments from large-scale API manufacturers and contract manufacturers in production of high potency API. The lower cost of labor cost and abundance of raw materials continue to facilitate the growth of API market in the Asia region. Faster approvals of API based peptide and diabetes management drugs. Over the recent past, a range of peptide drugs has been approved treatment of type 2 Diabetes Mellitus including Albiglutide (GSK), Dulaglutide (Eli Lilly), Exenatide (Amylin Pharmaceuticals) and Glucagon (Xeris Pharmaceuticals).

According to the report, small molecule API type segment holds promising investment opportunities for market participants on account of the numerous off-patent events incurred in the last five years coupled with a strong penetration of small scale manufacturers in Asia. On the basis region, APAC’s API market was valued at US$ 61.4 Bn in 2016 and is projected to witness the highest CAGR of 5.1 % during the forecast period to reach a valuation of US$ 95.6 Bn. This is primarily owing to the leadership of China and India in SMEs as well as their strong distribution network in overseas markets especially in US, South Africa, and Europe. Asian pharmaceuticals CMOs are competing on the basis of cost and timeline for API manufacturing and are attracting U.S.-based pharmaceuticals companies that are willing to outsource manufacturing requirements. Meanwhile, Europe is projected to be the second fastest growing market for API and is expected to reach US$ 42.5 Bn by 2025-end. Manufacturers in Europe are prioritizing high-quality standards, advanced manufacturing installations, and high purity of intermediates (API).

 
Competitive Dashboard : Johnson Matthey, Siegfried, Almac, PolyPeptide Laboratories, AmbioPharm, Inc., Corden Pharma, Pepscan, BCN peptide, Provence Technologies Groups, SennChemicals AG, Avecia OligoMedicines, Santaris Pharma - acquired by Roche in 2014, ST Pharm Oligo Center, Cepia Sanofi, Biospring, Pfizer CenterSource, Symbiotec Pharma Lab Pvt. Ltd., Gadea Grupo Farmacéutico, STEROID S.p.A., Dolder AG, Dalton Pharma Services, FarmaBios Spa, Dextra Laboratories Limited, GlycoSyn, Inalco Pharma, Sussex Research, Pfanstiehl, Inc., Noramco, Inc., Johnson Matthey, Siegfried, Rhodes Technologies, Ash Stevens, Fermion (public), FARMHISPANIA GROUP, Olon SpA, Lonza Group are some of the leading companies operating in the global active pharmaceutical ingredient market. Currently, many of the pharmaceutical companies are focused on outsourcing of API manufacturing to avoid large capital investments in setting up of API manufacturing facilities. This has accelerated the demand for CMOs in API manufacturing industry, which is dominated by small to medium manufacturers.

Comments

Post a Comment

Popular posts from this blog

Head Guards Market is Expected to Witness a Steady Growth by 2028

Market Overview Safety equipment plays an important role in protecting sports enthusiasts from various injuries. Head guard is the key protection equipment widely used in games like boxing, baseball and rugby. This equipment has gained traction among athletes from amateur to professional players in both, national and international competitions. Rising number of national and international sports competitions globally, the demand for head guards has surged, which will in turn increase the volume of head guard sells from retail outlets to the company online sales channel. Many sports associations such as World Rugby, International Baseball Federation and World Boxing Association have necessitated the use of head guards for players in sports matches. In baseball alone, there are over 35 million players at different levels, and the U.S. houses close to 14 million amateur and professional players. This massive number of participants in baseball creates a significant customer base for h...
Read more

Die Cut Box Market to Witness an Outstanding Growth by 2028

Die Cut Box Marke t: Overview Die cut box is an innovative packaging solution for multiple end-use sectors. Growing need for fast moving consumer goods, ingenious packaging formats from design, and size perspective,  die cut box continues to offer an advantageous edge in product positioning. Die cut box allows the leading brands and manufacturers to integrate novel design elements, which in turn assures a higher threshold of customer acquisition viz.a.viz. effective branding and marketing. Besides industry specific drivers and trends, macroeconomic factors will also continue to influence demand for the die cut box across industries. Such factor include but aren’t limited to per capita disposable income, food retail sector growth, modern retail establishment growth etc. Outpacing growth in the e-commerce sector has gained traction for the corrugated packaging industry. Die cut box cost wouldn’t be a big burn to the pocket of die cut box manufacturers despite the re-usability of ...
Read more

Gynaecological Cancer Drugs Market Accounting US$ 41,855.8 million by 2026

The new report by Persistence Market Research (PMR) expects the global gynaecological cancer drugs market to witness significant growth, registering 6.2% CAGR during the forecast period. The global gynaecological cancer drugs market is also expected to bring in US$ 41,855.8 million revenue by the end of 2026. Treatment of cancer is being increasingly focused on be leading pharmaceutical companies, researchers, healthcare institutes and governments of various countries. With increasing number of research and development activities in cancer treatment, especially in gynaecological cancer treatment, new treatments are reaching an increasing number of physicians faster than ever. Also, availability of advanced treatment options and drugs has resulted in the decline in cancer mortality rate across major developed countries. However, the scenario is not same in the developing nations. This is due to the high cost of cancer treatment and lack of availability of new treatments. Gynaecologi...
Read more